ARCT
Arcturus Therapeutics Holdings Inc (ARCT)
Healthcare • NASDAQ • $9.22+3.60%
- Symbol
- ARCT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $9.22
- Daily Change
- +3.60%
- Market Cap
- $262.06M
- Trailing P/E
- N/A
- Forward P/E
- -2.39
- 52W High
- $24.17
- 52W Low
- $5.85
- Analyst Target
- $23.20
- Dividend Yield
- N/A
- Beta
- N/A
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of P…
Company websiteResearch ARCT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.